Amer M. Mirza

1.9k total citations
32 papers, 1.3k citations indexed

About

Amer M. Mirza is a scholar working on Oncology, Immunology and Rheumatology. According to data from OpenAlex, Amer M. Mirza has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Immunology and 9 papers in Rheumatology. Recurrent topics in Amer M. Mirza's work include Rheumatoid Arthritis Research and Therapies (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Amer M. Mirza is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Amer M. Mirza collaborates with scholars based in United States, United Kingdom and Canada. Amer M. Mirza's co-authors include Martin McMahon, Charles A. Dinarello, Alan M. Solinger, Leonid L. Reznikov, Bahar Artım-Esen, Sandra Vanegas, Patrick J. Scannon, Ahmet Gül, İlknur Tuğal-Tutkun and Seema Kantak and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Molecular and Cellular Biology.

In The Last Decade

Amer M. Mirza

31 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amer M. Mirza United States	16	572	334	316	184	150	32	1.3k
Fumitaka Terabe Japan	12	234 0.4×	463 1.4×	365 1.2×	91 0.5×	137 0.9×	16	1.1k
R. Kath Germany	18	433 0.8×	175 0.5×	454 1.4×	176 1.0×	84 0.6×	55	1.3k
Erika Rimondi Italy	20	830 1.5×	310 0.9×	356 1.1×	61 0.3×	109 0.7×	65	1.3k
Tomohiro Kato Japan	20	322 0.6×	209 0.6×	114 0.4×	82 0.4×	216 1.4×	67	1.3k
C. Christian Johansson Sweden	19	535 0.9×	940 2.8×	590 1.9×	108 0.6×	93 0.6×	29	1.7k
Wei Ding China	22	935 1.6×	144 0.4×	323 1.0×	379 2.1×	129 0.9×	66	1.6k
Kevin Blighe United Kingdom	17	539 0.9×	201 0.6×	265 0.8×	190 1.0×	85 0.6×	40	1.3k
Weronika Kurowska Poland	16	388 0.7×	328 1.0×	178 0.6×	39 0.2×	68 0.5×	27	1.0k
Mohammad Javad Fattahi Iran	17	267 0.5×	274 0.8×	316 1.0×	61 0.3×	40 0.3×	58	852
Fazilat F. Mohammed Canada	8	317 0.6×	121 0.4×	284 0.9×	66 0.4×	153 1.0×	9	1.0k

Countries citing papers authored by Amer M. Mirza

Since Specialization

Citations

This map shows the geographic impact of Amer M. Mirza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amer M. Mirza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amer M. Mirza more than expected).

Fields of papers citing papers by Amer M. Mirza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amer M. Mirza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amer M. Mirza. The network helps show where Amer M. Mirza may publish in the future.

Co-authorship network of co-authors of Amer M. Mirza

This figure shows the co-authorship network connecting the top 25 collaborators of Amer M. Mirza. A scholar is included among the top collaborators of Amer M. Mirza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amer M. Mirza. Amer M. Mirza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Jun, Ivan G. Gomez, Jialu Wang, et al.. (2024). 9263 Characterization Of A Novel Oral Small Molecule PTH1R Agonist: Proof Of Concept For An Alternative To Injectable Peptide-Based Therapy For Hypoparathyroidism. Journal of the Endocrine Society. 8(Supplement_1). 1 indexed citations

Zhang, Jun, Ivan G. Gomez, Jialu Wang, et al.. (2024). 6821 Characterization Of A Novel Oral Small Molecule PTH1R Agonist: Proof Of Concept For An Alternative To Injectable Peptide-Based Therapy For Hypoparathyroidism. Journal of the Endocrine Society. 8(Supplement_1). 1 indexed citations

Jiang, Peng, Yu Zhang, Beibei Ru, et al.. (2021). Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nature Methods. 18(10). 1181–1191. 115 indexed citations

Zúñiga, Luis, Karan Uppal, Enping Hong, et al.. (2021). 769 A single dose of intratumoral TransCon™ TLR7/8 agonist monotherapy promoted sustained activation of antigen presenting cells resulting in CD4+ and CD8+ T cell activation and tumor growth inhibition. SHILAP Revista de lepidopterología. A804–A804.

Gladman, Dafna D., Andrew Hertz, Madhukar H. Trivedi, et al.. (2020). OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 79. 140–140. 1 indexed citations

Taylor, Peter C., et al.. (2020). THU0216 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN METHOTREXATE NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (FINCH3). Annals of the Rheumatic Diseases. 79. 333–334. 1 indexed citations

Taylor, Peter C., et al.. (2020). FRI0136 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1). Annals of the Rheumatic Diseases. 79. 650–651. 1 indexed citations

Terabe, Masaki, Faith C. Robertson, Emma De Ravin, et al.. (2017). Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. OncoImmunology. 6(5). e1308616–e1308616. 78 indexed citations

Flanders, Kathleen C., Yu-an Yang, Michelle A. Herrmann, et al.. (2016). Quantitation of TGF-β proteins in mouse tissues shows reciprocal changes in TGF-β1 and TGF-β3 in normal vs neoplastic mammary epithelium. Oncotarget. 7(25). 38164–38179. 21 indexed citations

10.

Bedinger, Daniel, et al.. (2015). Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms. mAbs. 8(2). 389–404. 30 indexed citations

11.

Budi, Erine H., Yoko Katsuno, Matthew Lee, et al.. (2015). ShcA Protects against Epithelial–Mesenchymal Transition through Compartmentalized Inhibition of TGF-β-Induced Smad Activation. PLoS Biology. 13(12). e1002325–e1002325. 42 indexed citations

12.

Mirza, Amer M., et al.. (2014). XOMA 089, a Novel Anti-TGF-beta Monoclonal Antibody, Inhibits Experimental Proliferative Vitreoretinopathy in Rabbits. Investigative Ophthalmology & Visual Science. 55(13). 1121–1121. 1 indexed citations

13.

Vanegas, Sandra, Betty A. Maddux, Nerissa Mendoza, et al.. (2013). XOMA 052, an anti‐IL‐1β monoclonal antibody, prevents IL‐1β‐mediated insulin resistance in 3T3‐L1 adipocytes. Obesity. 21(2). 306–309. 19 indexed citations

14.

Gül, Ahmet, İlknur Tuğal-Tutkun, Charles A. Dinarello, et al.. (2011). Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Annals of the Rheumatic Diseases. 71(4). 563–566. 176 indexed citations

15.

Bhaskar, Vinay, Johnny Yin, Amer M. Mirza, et al.. (2011). Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis. 216(2). 313–320. 177 indexed citations

16.

Blalock, William L., Patrick M. Navolanic, Linda S. Steelman, et al.. (2003). Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia. 17(6). 1058–1067. 50 indexed citations

17.

Shelton, John G., Linda S. Steelman, John Tayu Lee, et al.. (2003). Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene. 22(16). 2478–2492. 78 indexed citations

18.

Venetsanakos, Eleni, Amer M. Mirza, Christie Fanton, et al.. (2002). Induction of Tubulogenesis in Telomerase-Immortalized Human Microvascular Endothelial Cells by Glioblastoma Cells. Experimental Cell Research. 273(1). 21–33. 96 indexed citations

19.

Mirza, Amer M., Edward Frizell, Jing Zhu, et al.. (1997). A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. American Journal of Physiology-Gastrointestinal and Liver Physiology. 272(2). G281–G288. 139 indexed citations

20.

Mirza, Amer M., et al.. (1979). Hepatotoxicity of salicylazosulfapyridine: a case report and review of the literature.. The American Journal of Gastroenterology. 72(5). 561–564. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact